ArticlePloS one2026
Magnesium neuroprotection in retinal ganglion cells: A computational study of frequency-dependent therapeutic windows and intervention timing.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Retinal ganglion cells (RGCs) are vulnerable to excitotoxic damage mediated by excessive NMDA receptor activation and calcium overload. Extracellular magnesium (Mg2+) blocks NMDA receptors in a voltage-dependent manner, offering potential neuroprotection. However, the optimal Mg2+ concentrations and timing for effective intervention remain poorly defined. We developed a conductance-based computational model of an RGC incorporating Hodgkin-Huxley dynamics, AMPA and NMDA receptor-mediated synaptic transmission, and intracellular calcium dynamics. We systematically varied Mg2+ concentration (0.2-2.5 mM) and stimulation frequency (10-100 Hz) to identify therapeutic windows balancing neuroprotection with function preservation. At physiological frequencies (10-60 Hz), elevated Mg2+ reduced calcium (Ca2+) accumulation by 50-85% without affecting spike output. At excitotoxic frequencies (80 Hz), a narrow therapeutic window of 1.6-2.0 mM was identified, lying within a broader 1.4-2.0 mM spike-loss plateau (20% loss), where calcium additionally fell below the toxicity threshold while spike output was preserved. Intervention timing analysis revealed that Mg2+ protection efficacy is maximal with pre-treatment or immediate intervention (100%), and declines steeply with delay-reflecting the rapid early rise in Ca2+ rather than a fixed biological deadline (≥50% protection requires intervention within 0.2 s in our abrupt-onset protocol; ∼11% by 0.5 s). Re-analysis in terms of normalized Ca2+ progress revealed that the critical constraint for ≥50% protection is intervention before ∼35% of peak Ca2+ accumulation-a state-based threshold reflecting relative phase sensitivity that generalizes across timescales. Sensitivity analyses confirmed robustness of the therapeutic window across physiologically plausible parameter ranges, and numerical validation demonstrated accuracy of the computational approach. These findings demonstrate that Mg2+-mediated neuroprotection is highly dependent on both concentration and timing, with implications for therapeutic strategies targeting glutamate excitotoxicity in glaucoma and retinal ischemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.